Navigation Links
Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
Date:4/20/2008

Model Created Using Piecewise Smooth Subdivision Surface Provides Both

Shape and Volumetric Evaluation of Tetralogy of Fallot Patients

SEATTLE, April 8, 2008 /PRNewswire/ -- Three dimensional visualization of the right ventricle provides important shape and volumetric insights that help cardiologists diagnose and treat patients with tetralogy of Fallot (TOF), according to a paper published in the American Journal Cardiology (2008; Vol. 101, Issue 1, 107-113).

TOF is a disease that impacts the heart in multiple ways, such as creating a hole between the ventricles and developing levels of obstruction from the right ventricle to the lungs known as pulmonary stenosis. The three dimensional models created in the study provided volumetric data that was used to determine that patients with TOF had dilated right ventricles compared to individuals with normal function (end-diastolic volume index 216+/- 99 vs 81 +/- 16 ml/mm, p <0.001). The three dimensional models also provided an understanding of changes to the shape of the right ventricle that doctors can use to analyze how the heart adapts to hemodynamic overload.

Entitled "Three-Dimensional Analysis of Right Ventricular Remodeling in Repaired Tetralogy of Fallot," the paper was authored by Dr. Florence H. Sheehan, M.D. The research was a collaboration between investigators at Texas Children's Hospital, Oregon Health & Science University, University of Iowa, and University of Washington in Seattle, Wash. The study used piecewise smooth subdivision reconstruction to create three dimensional models of the hearts of 8 normal subjects and 15 patients with repaired TOF.

"Right ventricle measurement is a critical component in understanding the effectiveness of TOF repair," said Dr. Florence Sheehan, M.D., who is a professor at the University of Washington and chief scientist of VentriPoint Diagnostics Ltd. "We hope to now fully develop the novel diagnostic tools that make the process of
'/>"/>

SOURCE VentriPoint Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. Stevens researchers provide oversight for three-year mariculture program in Egypt and Israel
2. Columbia to award 2007 Horwitz Prize to three generations of teacher-student scientists
3. Three-way mating game of North American lizard found in distant European relative
4. Neurons hard wired to tell left from right
5. Northern right whales head south to give birth, leave genetic fingerprints with NOAA researchers
6. Bright lights: Mystery of glowing antibody solved by Scripps research scientists
7. UMMS and CIW grant key RNAi rights to Oxford Biomedica
8. UFs new owl butterfly species naming rights auctioned for $40,800
9. Everglades phosphorus limits on the right track, but more is needed
10. UF to auction naming rights for new butterfly species online
11. Researchers set new record for brightness of quantum dots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... In Santa Fe, Albuquerque, and other major cities in ... watered with treated municipal wastewater rather than precious potable ... more than 40% of all golf courses receive treated ... courses. , Additionally, golf courses and homeowners alike ... nutrient in fertilizer is nitrate. A New Mexico State ...
(Date:7/10/2014)... COLORADO SPRINGS, Colo. , June 27, 2014 ... announces that the National Institute of Standards and ... appointed 10 of its academic research and forensic ... Board (FSSB).  The Board is an element of ... These AAFS members are among the first appointments ...
(Date:7/10/2014)... YORK , June 27, 2014  Pomerantz ... Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) ... filed in United States District Court, Middle District ... is on behalf of a class consisting of ... acquired Provectus securities between December 17, 2013 and ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... Arctic is happening at a greater rate than other ... to continue in the future. As a result, ... sea level rise can be expected to continue. ... demonstrates for the first time the pervasive nature of ...
... Jan. 12, 2009 The 2009 winners of the ... Adusumilli, M.D. and Lee Goodglick, Ph.D. The $100,000 grants ... and the role of estrogen in lung cancer tumors, ... in lung cancer at Memorial Sloan-Kettering Cancer Center in ...
... new way to inhibit a molecule that is critical ... in the January 16th issue of the journal ... antiretroviral therapeutics that are likely to complement existing therapies ... Infection of human cells with HIV-1 requires multiple events ...
Cached Biology News:Arctic heats up more than other places 2National Lung Cancer Partnership and LUNGevity Foundation announce 2009 grant recipients 2Mutant host cell protein sequesters critical HIV-1 element 2
(Date:7/11/2014)... 11, 2014 Cayenne Medical, Inc., ... in the soft tissue reconstruction segment, announced the ... for surgeries involving the shoulder and extremities. The ... novel, inserter-controlled deployment method. The unique delivery eliminates ... anchor pull-out, or anchor displacement (also commonly know ...
(Date:7/10/2014)... Faso (PRWEB) July 10, 2014 ... today have access to an additional family planning ... access to contraception at all levels of the ... lower-dose formulation of a widely used contraceptive—Pfizer’s Depo-Provera® ... , Burkina Faso is the first of four ...
(Date:7/10/2014)... Product and process impurities in ... and are often “lost in the noise,” making ... presenters Dr. Rowel Tobias, Senior Scientist, Protein Chemistry ... of Quality at Nanotherapeutics, Inc., to lear about ... detection and quantitation while achieving the required specificity ...
(Date:7/10/2014)... 10, 2014 Deep Knowledge Ventures ... Forum on ‘Commercialising Longevity Research’ and welcomed a ... the London Bioscience Innovation Center for the event, ... Aging Analytics Ltd. The meeting highlighted the need ... research for age-related disease, as well as the ...
Breaking Biology Technology:Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6
... Dec. 30 Accuray Incorporated,(Nasdaq: ARAY ), a ... president and chief executive officer, Euan S. Thomson, Ph.D., is,scheduled ... in San,Francisco, on Wednesday, January 14, 2009 at 11:30 a.m. ... live webcast of the presentation will be available online from ...
... Israel, JERSEY CITY, New Jersey and PHILADELPHIA, ... ROSG),the leading developer of microRNA-based molecular diagnostics, ... test, miRview(TM) meso. The,test is now commercially ... , To order ...
... Thickness and Darkness of EyelashesIRVINE, Calif., Dec. 26 ... the U.S. Food and Drug Administration (FDA) has approved ... for hypotrichosis of the eyelashes. Eyelash hypotrichosis is ... LATISSE(TM) is the first and only science-based treatment ...
Cached Biology Technology:Accuray Incorporated's CEO to Speak at 27th Annual JP Morgan Healthcare Conference 2Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 2Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 3Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 4Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso 5Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 2Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 3Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 4Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 5Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 6Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 7Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 8Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 9
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Goat polyclonal to Als2 ( Abpromise for all tested applications). entrezGeneID: 57679 SwissProtID: Q96Q42...
Rabbit anti-NFkB p105/p50 (Ser337) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Biology Products: